Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Celldex Therapeutics (CLDX) Retained Earnings (2016 - 2025)

Celldex Therapeutics has reported Retained Earnings over the past 16 years, most recently at $3.6 million for Q4 2025.

  • Quarterly results put Retained Earnings at $3.6 million for Q4 2025, up 100.23% from a year ago — trailing twelve months through Dec 2025 was $3.6 million (up 100.23% YoY), and the annual figure for FY2025 was $3.6 million, up 100.23%.
  • Retained Earnings for Q4 2025 was $3.6 million at Celldex Therapeutics, down from $3.8 million in the prior quarter.
  • Over the last five years, Retained Earnings for CLDX hit a ceiling of $5.3 million in Q3 2024 and a floor of -$1.6 billion in Q1 2025.
  • Median Retained Earnings over the past 5 years was $0.0 (2022), compared with a mean of -$579.1 million.
  • Biggest five-year swings in Retained Earnings: surged 2006.25% in 2023 and later plummeted 71803.21% in 2025.
  • Celldex Therapeutics' Retained Earnings stood at -$1.1 billion in 2021, then skyrocketed by 100.11% to $1.3 million in 2022, then soared by 162.54% to $3.3 million in 2023, then tumbled by 47114.03% to -$1.6 billion in 2024, then soared by 100.23% to $3.6 million in 2025.
  • The last three reported values for Retained Earnings were $3.6 million (Q4 2025), $3.8 million (Q3 2025), and $3.3 million (Q2 2025) per Business Quant data.